Advanced BioMedical Technologies EBIT

Advanced BioMedical Technologies (ABMT) currently reports a EBIT of $-160K as of July 2022. That compares with $-440K in the prior-year period — up 63.5% year over year. That is below the sector sector average of $2.5T. Use the charts on this page to explore Advanced BioMedical Technologies's EBIT history and peer comparisons.

Advanced BioMedical Technologies's EBIT increased from $-440K to $-160K — a 63.5% year-over-year increase (period ending July 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Advanced BioMedical Technologies's EBIT of $-160K is lower than the its sector sector average of $2.5T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Advanced BioMedical Technologies reported $-160K in EBIT as of July 2022. That compares with $-440K in the prior-year period — up 63.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-160K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.5T. From there, open related valuation or income-statement pages for Advanced BioMedical Technologies, and consider following ABMT for alerts when major investors trade the stock.